Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia

Abstract Incorporation of the B-cell lymphoma 2 inhibitor venetoclax into the treatment of acute myeloid leukemia (AML) has been transformative. Initially studied in combination with low-intensity therapy in older adults and those ineligible for intensive therapy, venetoclax has proven to be efficacious and tolerable in this setting. Recently, venetoclax has been investigated in combination with more intensive regimens. However, these approaches come with a myriad of dosing strategies and questions surrounding the practicality of venetoclax administration. In this study, we provide an overview of the incorporation of venetoclax into AML treatment and a discussion of practical considerations and areas of unmet need. Significance: In recent years, there has been tremendous interest surrounding the integration of venetoclax into both non-intensive and intensive chemotherapy regimens for AML. However, with this increasing utilization of venetoclax, considerable questions surrounding key issues such as dosing strategies and the practicality of venetoclax administration have arisen. This review highlights the evolution of venetoclax-based regimens in AML and provides a commentary on notable practical considerations when utilizing this agent.